secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001683168-22-006708
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health completes Phase I trial for concussion drug PRV-002; drug safe and well-tolerated
--------------------------------------------------------------------------------

- Phase I SAD and MAD trial enrolled 40 healthy volunteers; drug was safe and well-tolerated with no severe adverse events.
- Pharmacokinetic analysis showed linear dose-plasma relationship; intranasal route suggests greater brain delivery.
- Company plans to proceed to Phase II trials, working with FDA and U.S. military for site identification and study design.
- Concussion treatment global market valued at $6.9B (2020), forecast $8.9B by 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822006708/0001683168-22-006708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822006708/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-006708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer